Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for RaQualia Pharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, RaQualia Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Buyback Yield % of -12.19 as of Jul. 18, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on RaQualia Pharma and its competitors. According to the industry distribution chart, RaQualia Pharma ranks #405 out of 740 companies in the Biotechnology industry, placing it in the top 54.7%.
Is RaQualia Pharma's Buyback Yield % too high?
RaQualia Pharma's current Buyback Yield % is -12.19. Based on the distribution chart, RaQualia Pharma ranks #405 out of 740 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #405 out of 740 companies for Buyback Yield %. This places RaQualia Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Buyback Yield % is -12.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円310.31, compared to a current price of 円458.00 — trading 47.6% above its estimated fair value. The current Buyback Yield % is -12.19. RaQualia Pharma's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Buyback Yield % is -12.19 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued.
The current stock price of 円458.00 is trading 47.6% above its estimated GF Value™ of 円310.31.
GuruFocus considers RaQualia Pharma to be Significantly Overvalued.
Key valuation signals for TSE:4579:
Buyback Yield %: -12.19
GF Value™: 円310.31 vs. price of 円458.00 (47.6% above fair value)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
59GF Score
Get the complete analysis for TSE:4579
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
